NEW DELHI– A surgically implanted device can significantly slow vision loss caused by macular telangiectasia type 2 (MacTel), a rare retinal disease that progressively destroys central vision, according to a new study published in NEJM Evidence.
MacTel, classified as an orphan retinal disorder, has long had no approved treatment options. The ENCELTO implant — recently approved by the U.S. FDA — delivers a continuous dose of ciliary neurotrophic factor (CNTF), a naturally occurring protein that protects retinal neurons.
The randomized Phase III trials, conducted at 47 sites worldwide with 228 participants, tracked patients over 24 months. Results showed that ENCELTO slowed the loss of photoreceptors — light-sensitive nerve cells essential for central vision — compared to sham-treated eyes.
In one trial, the implant reduced the rate of ellipsoid zone loss, a key marker of retinal degeneration, by 54.8%. The second trial showed a statistically significant 30.6% reduction.
“This is the first time we’ve seen a therapy meaningfully alter the course of MacTel,” said Professor Martin Friedlander of Scripps Research, adding that the findings validate neuroprotection as a viable strategy for preserving vision in degenerative retinal diseases.
The device uses genetically modified retinal pigment epithelial cells, encased in a collagen capsule to prevent immune rejection, enabling long-term, localized CNTF delivery. (Source: IANS)
